Announcement from Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. on semi-annual performance report for 2024.

Sensex a share12:00 ET · Announcements

Zhangzhou Pientzehuang Pharmaceutical (600436.SH): Phase I clinical trial results show that PZH2107 has good safety and tolerability.

Zhangzhou Pientzehuang Pharmaceutical (600436.SH) announced that the company recently signed a strategic cooperation agreement with Shanghai Lidao Pharmaceutical Technology Co., Ltd. ("Lidao Pharmaceutical"...}

Zhitong FinanceJul 24 06:45 ET

Zhangzhou Pientzehuang Pharmaceutical (600436.SH): Obtained the Phase I Clinical Study Report of PZH2107.

On July 24th, Gelonhui announced that the company has collaborated with Shanghai Lidao Medical Technology Co., Ltd. (referred to as 'Lidao Medicine') on the PZH2107 research and development project (LDS片 internal research and development project code: LDS片). Phase I clinical trials have been completed, and the PZH2107 Phase I clinical study report has been obtained. The research shows that the safety and tolerability of PZH2107 in Chinese healthy subjects are good in all dose groups.

Gelonghui FinanceJul 24 06:30 ET

Zhangzhou Pientzehuang Pharmaceutical (600436.SH): net income of 1.72 billion yuan in the first half of the year, a year-on-year increase of 11.61%.

On July 24th, Gelonhui announced its 2024 interim financial report. The total operating revenue for the reporting period was 5.65 billion yuan, a year-on-year increase of 11.99%. The net income attributable to shareholders of listed companies was 1.72 billion yuan, a year-on-year increase of 11.61%. The net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 1.751 billion yuan, a year-on-year increase of 11.03%. The company's total operating revenue increased by 11.99% year-on-year. The main reason for this is the strengthening of market planning and the expansion of sales channels. The company's core product series, Zhangzhou Pientzehuang Pharmaceutical, and its controlling subsidiary, Fujian Pientzehuang Cosmetics, all contributed to this growth.

Gelonghui FinanceJul 24 06:30 ET

Express News | Pientzehuang Pharma Prelim H1 Net Profit up 11.6% Y/Y

ReutersJul 24 06:29 ET

Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years

Simply Wall StJul 11 22:31 ET